

## Original Research Article

### Phytochemical and Pharmacological Potential of *Enhydra fluctuans* available in Bangladesh

#### ABSTRACT

**Objectives:** The possible phytochemical ~~nature~~constituents, thrombolytic and membrane stabilizing ~~activity-activities~~ of the crude ethanolic extract of *Enhydra fluctuans* (CE) were investigated along with the anti-microbial, antioxidant and cytotoxic potentials of its petroleum ether (PESF), carbon tetrachloride (CTCSF), chloroform (CSF) and aqueous (AQSF) soluble fractions.

**Materials & Methods:** The coarse leaf powder was extracted at room temperature with ethanol. Solvent-solvent partitioning was done to obtain the four soluble fractions ~~by the modified Kupchan method~~. Anticoagulant potential was determined by the *in vitro* thrombolytic model, membrane stabilization method was used to assess *in vitro* anti-inflammatory activity, the disc diffusion method was used for anti-microbial screening, antioxidant potential was determined by 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method and brine shrimp lethality bioassay method was used for cytotoxic activity determination.

**Results:** Chemical screening of the crude extract evidences the presence of alkaloids, saponins, tannins, flavonoids, reducing sugars and gums. It showed significant clot lysis property of 49.29%. It also significantly inhibited heat and hypotonic solution induced lysis of the human red blood cell membrane with values of 71.67% and 47.93%, respectively. CTCSF and PESF showed mild antimicrobial activity. AQSF showed most prominent antioxidant activity with IC<sub>50</sub> value of 12.27 µg/mL. CTCSF showed LC<sub>50</sub> value of 0.84 µg/mL, with most potent cytotoxic activity.

**Conclusion:** Significant thrombolytic, membrane stabilizing, antioxidant and cytotoxic activities of the plant was found from this study. *In vivo* activities and isolation of active compound(s) from this extract are yet to be investigated.

**Keywords:** *Enhydra fluctuans*, thrombolytic ~~activity~~, membrane stabilizing ~~activity~~, antioxidant ~~activity~~ and cytotoxic ~~activity~~.

#### INTRODUCTION

Medicinal plants have played an important role in treating various diseases since ancient times. Increased drug resistance and side effects of existing pharmaceutical drugs have escalated the research based study on traditionally available plants. Myocardial or cerebral infraction and other atherothrombotic diseases are consequences of thrombus formed in blood vessel<sup>1,2</sup>. Fibrinolytic drugs ~~like such as~~ tissue plasminogen activator (t-PA), urokinase, streptokinase ~~ete and others~~

**Formatted:** Adjust space between Latin and Asian text, Adjust space between Asian text and numbers

**Formatted:** Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

40 dissolve thrombin in acutely occluded coronary arteries and restore blood supply to ischemic  
41 myocardium, to limit necrosis and improve prognosis<sup>3</sup>. Yet all the available thrombolytic agents  
42 have significant deficiencies, including the necessity of large doses to be maximally effective,  
43 limited fibrin specificity and a significant associated bleeding tendency. Therefore, studies are  
44 going on to develop improved thrombolytic drugs in order to minimize deficiencies of the  
45 available drugs.

46 | Inflammation is a pathological disorder, in which inflammatory cells produce a complex mixture  
47 of growth and differentiation cytokines as well as physiologically active arachidonate  
48 metabolites, also generate reactive oxygen species (ROS) that can damage cellular biomolecules  
49 which in turn augment the state of inflammation<sup>4</sup>. Compounds that possess radical scavenging  
50 ability may therefore expect to have the therapeutic potentials against inflammation<sup>5</sup>. Moreover,  
51 stabilization of lysosomal membrane limits inflammatory response by inhibiting the release of  
52 lysosomal constituents of activated neutrophil such as bactericidal enzymes and proteases, which  
53 are responsible for further tissue inflammation and damage<sup>6</sup>.

54 Bacteria are responsible for many infectious diseases in 21<sup>st</sup> century<sup>7</sup>. Antibiotic resistance has  
55 become a major clinical and public health problem for most people now-a-days<sup>8,9</sup>. This  
56 | ~~Multidrug-multidrug Resistance-resistance~~ (MDR) is clearly related to the misuse of different  
57 antibiotics<sup>10,11</sup>. The increasing clinical importance of drug resistant bacterial pathogens  
58 | necessitates emergence of additional antibacterial therapy. The antibacterial screening which is  
59 the first stage of antibacterial research is performed to ascertain the susceptibility of various  
60 bacteria to any agent.

61 Free radicals are highly toxic and reactive; and cause diseases like aging, atherosclerosis, cancer,  
62 diabetes, liver cirrhosis, cardiovascular disorders, etc. by attacking different macro-molecules  
63 including lipids, proteins and DNA resulting in the cellular damage<sup>12,13</sup>. Antioxidants protect  
64 | body by delaying or reducing the oxidation of the substrate in turn neutralize or terminate the  
65 chain reaction before vital molecules within the body are damaged<sup>14</sup>. Currently available  
66 synthetic antioxidants like butylated hydroxyl anisole (BHA), butylated hydroxy toluene (BHT),  
67 tertiary butylated hydroquinone and gallic acid esters show low solubility and moderate  
68 antioxidant activity with suspected negative health effects<sup>15</sup>. BHA and BHT are suspected of  
69 being responsible for liver toxicity and carcinogenesis<sup>16,17</sup>. Investigations to screen out naturally  
70 occurring antioxidants are now mostly demanding.

71 Bioactive compounds are always toxic to living body at some higher doses and it justifies the  
72 statement that 'Pharmacology is simply toxicology at higher doses and toxicology is simply  
73 pharmacology at lower doses'. Brine shrimp lethality bioassay implies cytotoxicity as well as a  
74 wide range of pharmacological activities such as antimicrobial, antiviral, ~~pesticidal~~ pesticides and  
75 | anti-tumor ~~ete~~ and others of the compounds<sup>18,19</sup>.

76 *Enhydra fluctuans* Lour (Family: Asteraceae) is a small genus of marsh herb, available in  
77 | tropical and subtropical regions; ~~like~~ namely Bangladesh, India, Malaysia, China and the rest of  
78 South East Asia and Tropical Africa<sup>20,21</sup>. The herb is relatively glabrous sometimes pubescent  
79 | glandular. Stems are usually 0.3-to 0.6 m, elongated simple or divaricating rooting at the nodes<sup>22</sup>.  
80 Traditional uses indicate that the leaves of the plant are good as laxative. The expressed juice of  
81 | the leaves is an excellent demulcent in ~~gonorrhoeagonorrhoea~~ and also used in the treatment of  
82 skin and nervous system<sup>23</sup>. These activities can be attributed mainly to the presence of  
83 phytochemicals such as flavonoids, alkaloids, saponins, tannins, phenols and carbohydrates. But

84 there are insufficient ~~records~~ in literature of this plant, regarding its pharmacological activities  
85 and phytochemical characteristics. Thus the present study focuses on screening of the ethanolic  
86 extract of *Enhydra fluctuans* Lour for its phytochemical and pharmacological potential.

Comment [SaA1]: Is this true?

87

## 88 MATERIALS AND METHODS

### 89 Instrumentation

90 The extract was ~~condensed-concentrated~~ in rotary vacuum evaporator (Heidolph Instruments  
91 GmbH & Co. KG, Germany). Samples were centrifuged on a bench top centrifuge machine  
92 (HERMLE Labortechnik GmbH, Germany). The absorbance was recorded by a UV-~~Visible~~  
93 ~~visible~~ spectrophotometer (Analytic Jena AG, Germany). Ketoconazole was obtained from  
94 Beximco Pharmaceuticals Ltd., Bangladesh. Streptokinase vial (Beacon Pharmaceutical Ltd) was  
95 purchased from local pharmacy. Trolox and BHA were obtained from Calbiochem, Merck,  
96 Germany and VWR International Ltd., England, respectively. Nutrient agar and potato dextrose  
97 agar and ~~Kanamycin-kanamycin~~ 30 µg standard disc were purchased from HiMedia Laboratories  
98 Pvt. Ltd., India. All other reagents were purchased from Sigma-Aldrich, USA and all other  
99 solvents used were of analytical grade and purchased from Active Fine Chemicals Ltd.,  
100 Bangladesh.

### 101 Collection and Identification

102 ~~For this investigation,~~ *Enhydra fluctuans* leaves were collected from Narayanganj, Bangladesh  
103 on February 2015. Plant was identified by experts. ~~After collection~~ The leaves were thoroughly  
104 washed with clean water, ~~then shade~~ dried ~~in the shade~~ for several days and oven dried for 24  
105 hours at not more than 40 °C ~~for better grinding~~. The dried leaves were then ground to a coarse  
106 powder. The powder (140 g) was subjected to cold maceration by soaking in 1200 mL of ethanol  
107 in a clean, amber colored reagent bottle. The container was kept for a period of 10 days with  
108 occasional shaking and stirring. The whole mixtures were then filtered through a fresh cotton  
109 plug and finally with a Whatman No.1 filter paper. The filtrate was concentrated at 40 °C under  
110 reduced pressure to evaporate approximately 70% of the solvent to obtain the crude extract, CE.  
111 5.0 g of CE was dissolved in 10% aqueous ethanol. Solvent-solvent partitioning of this solution  
112 was done using the protocol designed by Kupchan and modified by Van Wagenet al., (1993)  
113 with petroleum ether, then with carbon tetrachloride and finally with Chloroform to obtain three  
114 fractions (PESF, CTCSF and CSF) and the remaining part was named as aqueous soluble  
115 fraction (AQSF)<sup>24</sup>.

Comment [SaA2]: To state the name and designation!

### 116 Phytochemical Screening

117 Approximately 5 mg of CE was diluted in ethanol to perform the following ~~tests~~ for  
118 identification of different chemical groups<sup>25,26</sup>.

### 119 Tests for tannins

120 Ferric ~~Chloride-chloride~~ Test: ~~About~~ 5 mL of the solution was taken in a test tube ~~, followed by~~  
121 ~~addition of~~ 1 mL of 5% ferric chloride solution ~~was added to it~~. Greenish black precipitate ~~will~~  
122 indicates the presence of tannins.

123 Potassium ~~Dichromate-dichromate~~ Test: ~~About~~ 1 mL of 10% potassium dichromate solution was  
124 added with 5 mL of the extract solution in a test tube. Yellow precipitate ~~will~~ suggest the  
125 presence of tannins.

126 | Lead ~~Acetate-acetate~~ Test: About 1 mL of 10% lead acetate solution was added to 5 mL of  
127 | extract solution. The Ppresence of tannins ~~will be~~ere indicated by yellow precipitate.

#### 128 | **Test for Flavonoids**

129 | A few drops of concentrated hydrochloric acid were added to a small amount of CE. Immediate  
130 | red color formation is caused by flavonoids.

#### 131 | **Test for Saponins**

132 | About 1 mL of the solution was diluted with ~~distilled water to~~ 20 mL distilled water and shaken  
133 | in a graduated cylinder for 15 minutes. One-centimeter layer of foam formation will indicate the  
134 | presence of saponins.

#### 135 | **Tests for Gums**

136 | About 5 mL solution of the extract was ~~taken and then~~added to molisch reagent and sulfuric acid  
137 | ~~were added~~. Red violet ring at the junction of the two liquids evidences presence of gums.

#### 138 | **Tests for Steroids**

139 | About 1 mL concentrated ~~sulphuric-sulfuric~~ acid was added to 1 mL solution of ~~the~~ chloroform  
140 | extract. Red color in the lower layer will indicate the presence of steroids.

#### 141 | **Tests for alkaloids**

142 | Mayer's test: About 2 mL solution and 0.2 mL of dilute hydrochloric acid were taken in a test  
143 | tube. Then 1 mL of Mayer's reagent was added. Yellowish buff colored precipitate ~~is indicative~~  
144 | indicates of the presence of alkaloids.

145 | Dragendroff's test: About 2 mL solution and 0.2 mL of dilute hydrochloric acid were taken in a  
146 | test tube. Then 1 mL of Dragendroff's reagent was added. Orange brown precipitate evidences  
147 | the presence of alkaloids.

148 | Hager's test: About 2 mL solution of the extract and 0.2 mL of dilute hydrochloric acid were  
149 | taken in a test tube. Then 1 mL of picric acid solution or Hager's reagent was added. Yellowish  
150 | precipitate evidences presence of alkaloids.

#### 151 | **Test for ~~Reducing-reducing Sugars~~sugar**

152 | About 2 mL of aqueous extract ~~of the plant material~~ was added to 1 mL of a mixture of equal  
153 | volumes of Fehling's solutions A and B, boiled for few minutes. Brick red colored precipitate  
154 | will indicate presence of reducing sugar.

#### 155 | **Thrombolytic activity**

156 | ~~As a part of exploration of cardio protective drugs from natural resources the e~~The extract of *E.*  
157 | *fluctuans* was assessed for thrombolytic activity using *in vitro* thrombolytic model<sup>27</sup>. Taking  
158 | account of all ethical considerations, and aseptic precautions, 20 mL of venous blood was drawn  
159 | from healthy human volunteer without a history of oral contraceptive or anticoagulant therapy.  
160 | This withdrawn blood was then distributed in pre-weighed sterile vials (1 mL/tube) and  
161 | incubated at 37°C for 45 minutes. After clot formation, the serum was completely removed  
162 | without disturbing the clot and clot weight was determined (clot weight = weight of clot  
163 | containing vial – weight of vial alone). About 100 mg of CE was dissolved in 10 mL of ethanol  
164 | and kept overnight. ~~Then the~~The soluble supernatant was decanted and filtered. Approximately  
165 | 100 µL of the solution was added to a vial containing pre-weighed clot. Lyophilized

166 | ~~Streptokinase~~ streptokinase (SK) vial of 15,00,000 I.U. was reconstituted with 5 ~~ml~~-mL sterile  
167 | distilled water. ~~About~~ 100  $\mu$ L (30,000 I.U) of the solution was added as positive control and 100  
168 |  $\mu$ L of distilled water was added as a negative non thrombolytic control to the vial containing pre-  
169 | weighed clot separately. All the three vials were then incubated at 37- $^{\circ}$ C for 90 minutes and  
170 | observed for clot lysis. After incubation, the released fluid was removed and vials were again  
171 | weighed to observe the weight difference after clot disruption. This difference of weight before  
172 | and after clot lysis was expressed as ~~the~~ percentage of clot lysis as ~~shown below~~ the following:

173 | ~~%-Percentage~~ of clot lysis = (wt. of released clot/clot wt.)  $\times$  100

174 | *Membrane stabilization activity*

175 | To assess the anti-inflammatory activity, membrane stabilization potential of CE was evaluated  
176 | by measuring the heat and hypotonic solution induced ~~haemolysis~~hemolysis of erythrocyte  
177 | following standard protocol<sup>28</sup>.

178 | *Preparation of erythrocyte suspension*

179 | Fresh whole blood (20 mL) was collected intravenously in syringe containing 3.1% sodium  
180 | citrate solution as anti-coagulant from healthy human volunteer without history of non steroidal  
181 | anti-inflammatory drugs (NSAIDs) therapy for 2 weeks prior the experiment. The blood cells  
182 | were washed three times with isotonic buffer solution, 154 mM NaCl in 10 mM sodium  
183 | phosphate buffer (pH 7.4) through centrifugation at 3000 g for 10 min.

184 | *Heat induced ~~haemolysis~~hemolysis*

185 | CE was dissolved in isotonic solution. Isotonic buffer containing aliquots (5 mL) of the extract at  
186 | 1.0 mg/mL was taken in ~~6-six~~ centrifuge tubes in three sets of two. Two sets of control tubes  
187 | ~~were taken~~ containing 5 mL of the vehicle ~~control~~ and 5 mL of 0.1 mg/mL of acetyl salicylic  
188 | acid (ASA), respectively. Erythrocyte suspension was added to each tube and mixed gently by  
189 | inversion. One pair of the tubes was incubated at 56 $^{\circ}$ C for 30 min in a water bath, while the other  
190 | pair was maintained at ~~(0-to 5)-~~ $^{\circ}$ C in an ice bath. The reaction mixture was centrifuged for 5 min  
191 | at 2500 g and the absorbance of the supernatant was measured at 560 nm. The percentage  
192 | inhibition or acceleration of hemolysis was calculated according to the ~~equation~~:

193 | ~~%-Percentage of~~ Inhibition of hemolysis =  $100 \times [1 - (OD_2 - OD_1) / (OD_3 - OD_1)]$

194 | Where,

195 | OD<sub>1</sub>= optical density of unheated test sample; OD<sub>2</sub>= optical density of heated test sample; OD<sub>3</sub>=  
196 | optical density of heated control sample

197 | *Hypotonic solution induced ~~haemolysis~~hemolysis*

198 | ~~About~~ 5 mL hypotonic solution (distilled water) containing 1.0 mg/mL of CE were put in  
199 | centrifuge tube in triplicates. ~~About~~ 5 mL of hypotonic solution and 5 mL of acetyl salicylic acid  
200 | (ASA) at 0.1 mg/mL ~~e~~concentration was taken as negative and positive controls respectively in  
201 | separate centrifuge tubes. Erythrocyte suspension (0.5 mL) was added to each of the tubes and  
202 | mixed gently. The mixture was incubated for 10 min at room temperature and then centrifuged  
203 | for 10 min at 3000 g. The absorbance of the supernatant was measured at 540 nm. The  
204 | percentage inhibition of ~~haemolysis~~hemolysis or membrane stabilization was calculated using  
205 | the following ~~equation~~:

206 | Inhibition of ~~haemolysis~~hemolysis (%) =  $100 [1 - \{(OD_2 - OD_1) / (OD_3 - OD_1)\}]$

Comment [SaA3]: Please include reference for the formula!

Comment [SaA4]: Please include the reference!

Comment [SaA5]: Please include the reference!

207 Where OD<sub>1</sub> = absorbance of test sample in isotonic solution; OD<sub>2</sub> = absorbance of test sample in  
208 hypotonic solution; OD<sub>3</sub> = absorbance of control hypotonic sample

#### 209 Antimicrobial assay

210 The disc diffusion technique<sup>29</sup> was used for preliminary screening of antimicrobial activity. Two  
211 Gram Positive bacterial strains (*Bacillus megaterium*, *Staphylococcus aureus*), two Gram  
212 Negative bacterial strains (*Escherichia coli*, *Pseudomonas aeruginosa*) and two fungal strains  
213 (*Aspergillus niger* and *Aspergillus flavus*) were collected as pure cultures. PESF, CTCSF, CSF,  
214 AQSF fractions of the crude extracts were dissolved separately in specific volume of  
215 dichloromethane or methanol depending on their solubility. The diluted samples were applied on  
216 the sterile discs at a concentration of 500 µg/disc. Kanamycin (30 µg/disc) and Ketoconazole  
217 ketoconazole (30 µg/disc) were used as standard antibiotics for antibacterial and antifungal  
218 screening, respectively. Solvent was used as negative control. The antimicrobial activity of the  
219 test agent was determined by measuring the diameter of zone of inhibition expressed in  
220 millimetermm.

Comment [SaA6]: To state culture agar and conditions for assay?

#### 221 Antioxidant scavenging activity

222 Antioxidant potential was studied using DPPH radical scavenging activity with slight  
223 modification of the methods described by Brand-William *et al*<sup>30</sup>. Here, solution of varying  
224 concentrations such as 200 µg/mL, 100 µg/mL, 50 µg/mL, 25 µg/mL, 12.5 µg/mL, 6.25 µg/mL,  
225 3.125 µg/mL, 1.5625 µg/mL and 0.78125 µg/mL were obtained by serial dilution technique in  
226 test tubes, where 2 mL of each of the test sample solution was mixed with 2 mL of a DPPH-  
227 methanol solution (20 µg/mL) to obtain the above mentioned concentrations. Test tubes were  
228 allowed to stand for 20 minutes in dark for the reaction to occur. The absorbance was determined  
229 at 517 nm and percentage of inhibition was calculated by using the following equation:

Comment [SaA7]: Please include the reference!

230

231  $\% \text{-Percentage of inhibition of radical scavenging} = [1 - (\text{ABS}_{\text{sample}} / \text{ABS}_{\text{control}})] \times 100.$

232

233 Then % inhibitions were plotted against respective concentrations used and from the graph IC<sub>50</sub>  
234 was calculated. Here, ascorbic acid and BHA were used as the positive controls.

#### 235 Cytotoxic activity

236 Brine shrimp lethality bioassay technique was applied for the determination of general toxic  
237 properties of the plant ~~extractives~~ extracts against *Artemiasalina*<sup>19,31</sup>. The test samples were  
238 dissolved in dimethyl sulfoxide (DMSO) following serial dilutions to obtain concentrations of  
239 400, 200, 100, 50, 25, 12.5, 6.25 and 3.125 µg/mL in separate test tubes containing 10 shrimps in  
240 simulated brine water (5 mL). The test tubes were incubated at room temperature for 24 hours.  
241 The LC<sub>50</sub> of the test samples was determined by a plot of percentage of the shrimp mortality  
242 against the logarithm of the sample concentrations. Vincristine ~~sulphate~~ sulfate was used as  
243 positive control in this assay to compare the cytotoxicity of the test samples.

Comment [SaA8]: To state the culture method and medium used for the assay

244

245

246

247 | **RESULTS AND DISCUSSION**

248 | *Phytochemical screening*

249 | Preliminary phytochemical screening evidences the presence of alkaloids, saponins, tannins,  
250 | flavonoids, reducing sugar and gums (**Table1**).

251 | **Table 1:** Results of chemical group tests.

**Comment [SaA9]:** State the amount: low, intermediate or highly presence!

**Formatted:** Font: Bold

**Formatted:** Font: Bold


Tested groups	Alkaloids	Steroids	Saponin	Tannins	Flavonoids	Reducing Sugars	Gums
Ethanollic Extract of <i>Enhydra fluctuans</i>	+	-	+	+	+	+	+

252 | Note: + =Indicates the presence of the tested group, - = Indicates the absence of the tested  
253 | group.

254 | *Thrombolytic activity*

255 | The erythrocyte membrane resembles to lysosomal membrane and as such, the effect of drugs on  
256 | the stabilization of erythrocyte could be extrapolated to the stabilization of lysosomal  
257 | membrane<sup>32,33</sup>. Addition of 100µL SK solution, a positive control to the clots and subsequent  
258 | incubation resulted in 66.67% lysis of clot. On the other hand, negative control exhibited a  
259 | negligible lysis of clot (8.33%). When clots were treated with the test sample significant clot  
260 | lysis activity (46.91%) was observed. When compared with the negative control (water) the  
261 | mean of percentage (%) of clot lysis was significant ( $p < 0.001$ ). [Figure 1 shows](#)?????????

**Comment [SaA10]:** Please describe the figure in detail!



262 | **Figure 1:** Thrombolytic activity (in terms of % of clot lysis) of CE with standard deviation error  
263 | bar where n=3.  
264 |

**Formatted:** Font: Bold

**Formatted:** Justified



265 *Membrane stabilizing activity*

266 Flavonoid rich ethyl acetate extract of *E. fluctuans* collected from West Bengal, India showed  
267 significant anti-inflammatory activity in carrageenan and histamine induced paw edema in rats<sup>34</sup>.  
268 The ethanol extracts of *E. fluctuans* at concentration 1.0 mg/mL significantly protected the lysis  
269 of human erythrocyte membrane by hypotonic solution and heat induced haemolysis  
270 compared to the standard acetyl salicylic acid (0.10 mg/ml). For heat induced condition CE  
271 demonstrated 71.80% inhibition of haemolysis of RBCs, whereas acetyl salicylic acid  
272 inhibited 77.20%. On the other hand, during hypotonic solution induced haemolysis,  
273 CE inhibited 47.60% haemolysis of RBCs as compared to 71.90% produced by acetyl  
274 salicylic acid.

275





Figure 2: Heat--induced haemolysis with standard deviation error bar.

Figure 3: Hypotonic solution induced haemolysis with standard deviation error bar.

Comment [SaA11]: Please explain Figures 2 and 3 in the paragraph!

Comment [SaA12]: The figures y-axis and x-axis are not labelled. Standardize the fonts and format!

Formatted: Font: Bold

Formatted: Font: Bold

276 *Antimicrobial assay*

277 Table-2 shows antimicrobial activity of the tested samples. PESF showed mild activity against  
278 gram-Gram negative bacteria *Escherichia coli* and *Pseudomonas aeruginosa*. CTCSF exhibited  
279 mild activity against both gram-Gram positive and gram-Gram negative bacteria. All the  
280 fractions were inactive against fungal strains. This result is consistent with some antimicrobial  
281 screening reports on the plant<sup>35</sup>.

282

283

284

285

286

287

288

289

Formatted: Font: Bold

Comment [SaA13]: Please state the ATCC number for the bacteria?



290 **Table 2:** Antimicrobial activity of test samples of *E. fluctuans*.


Test organisms	Diameter of zone of inhibition(mm)				Ketoconazole 30µg/disc
	PESF 100µg/dis c	CTSF 100µg/di sc	CSF 100µg/di sc	AQSF 100µg/di sc	
<b>Gram positive Bacteria</b>					
<i>Bacillus megaterium</i>	–	7 mm	–	–	40 mm
<i>Staphylococcus aureus</i>	–	8 mm	–	–	28 mm
<b>Gram-negative Bacteria</b>					
<i>Escherichia coli</i>	7 mm	8 mm	–	–	26 mm
<i>Pseudomonas aeruginosa</i>	7 mm	7 mm	–	–	27 mm
<b>Fungal Strain</b>					
<i>Aspergillus niger</i>	–	–	–	–	26 mm
<i>Aspergillus flavus</i>	–	–	–	–	36 mm

291

292 **Antioxidant assay**

293 The antioxidant activity was expressed from the IC<sub>50</sub> value of all samples. Comparison of IC<sub>50</sub>  
 294 values of different fractions and extracts with standard was shown in **Figure 4**. AQSF was  
 295 found to be most potent with lowest IC<sub>50</sub> value. IC<sub>50</sub> values of PESF, CTCSF, CSF, AQSF,  
 296 trolox, BHA, Vitamin C are 59.59 µg/mL, 29.28 µg/mL, 26.62 µg/mL, 12.27 µg/mL, 2.04  
 297 µg/mL, 2.21 µg/mL and 0.17 µg/mL respectively. Previous report of *E. fluctuans* collected from  
 298 West Bengal, India suggest significant antioxidant property of ethyl acetate extract<sup>36</sup>. Also there  
 299 has been report of isolation of antioxidative carbohydrate polymer from *E. fluctuans* which is **the**  
 300 most consistent with our finding<sup>37</sup>.

301



302

303 **Figure 4:** Comparison of LC<sub>50</sub> value of different extracts of *E. fluctuans* & standards.

304

305 Cytotoxicity assay

306 In case of brine shrimp lethality bioassay, the lethality of the PESF, CTCSF, CSF and AQSF  
307 fractions against *A. salina* were shown in **Table 3**. Lethality assay is proved to be suggestive of  
308 different pharmacological properties by isolation of cytotoxic, antimalarial or insecticidal  
309 compounds from the cytotoxic plant extracts<sup>38</sup>. Flavonoids isolated from *E. fluctuans* exhibited  
310 anticancer activity tested *in vitro* in mice<sup>39</sup>. There is also report of *E. fluctuans* leaves stimulating  
311 cell-mediated immune system by increasing neutrophil's phagocytic activity<sup>40</sup>. Here,  
312 CTCSF fraction was most potent with the lowest LC<sub>50</sub> value which is consistent with the existing  
313 reports on *E. fluctuans*.

Formatted: Font: Bold

Comment [SaA14]: Explanation for your results obtained?

314  
315 **Table 3:** Lethal concentration for 50% mortality (LC<sub>50</sub>) of different extracts of *E. fluctuans*.

Sample	PESF	CTCSF	CSF	AQSF
LC <sub>50</sub> value (µg/mL)	0.97	0.84	1.43	1.16

Formatted: Centered, Line spacing: single

Formatted: Line spacing: single

316  
317 Preliminary chemical screening and *in-vitro* bioactivity study data suggests *Enhydra fluctuans*  
318 potential pharmacological activity. It showed significant cytotoxic activity with good  
319 thrombolytic and anti-inflammatory potential. Further higher and detailed experiments for  
320 isolation of bioactive compounds from *Enhydra fluctuans*.

321  
322 **Conflict of Interest**

323 There is no conflict of interest to declare by the authors.

324  
325 **References**

- 326 1. Davies MJ, Thomas AC. Plaque fissuring—the cause of acute myocardial infarction, sudden  
327 ischaemic death, and crescendo angina. British Heart Journal 1985; 53:363-373.
- 328 2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT.  
329 Prevalence of total coronary occlusion during the early hours of transmural myocardial  
330 infarction. The New England Journal of Medicine 1980; 303:897-902.
- 331 3. Laurence DR, Bennett PN. Clinical Pharmacology. Ed 7, Churchill Livingstone, New York,  
332 1992.
- 333 4. Cochrane CG. Cellular injury by oxidants. American Journal of Medicine 1991;91: 23 – 30.
- 334 5. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxidative Medicine  
335 and Cellular Longevity 2011; 2011: Article ID 809696.
- 336 6. Murugasan N, Vember S, Damodharan C. Studies on erythrocyte membrane IV: *In vitro*  
337 haemolytic activity of oleander extract. Toxicology Letters 1981; 8:33-38.
- 338 7. Morris AK, Masterton RG. Antibiotic resistance surveillance: action for international studies.  
339 Journal of Antimicrobial Chemotherapy 2002; 49:7-10.
- 340 8. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses.  
341 Nature Medicine 2004; 10:122-129.

Formatted: Font: Italic

- 342 9. Taubes G. The bacteria fight back. *Science* 2008; 321: 356-361.
- 343 10. Levy SB. The antibiotic paradox-How miracle drugs are destroying the miracle. Plenum Press,  
344 New York, 1992.
- 345 | 11. Levy SB. Antibiotic resistance: an ecological imbalance. In: *Antibiotic Resistance: Origins,*  
346 *Evolution, Selection and Spread*, editors: Chadwick D, Goode J, John Wiley and Sons,  
347 Chichester, 1997, 1-14.
- 348 12. Gutteridge JM. Free radicals in disease processes: A complication of cause and  
349 | consequence. *Free Radical Research Communications* 1993; 19(3):141-158.
- 350 13. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and diseases.  
351 | *Journal of the American Oil Chemists' Society* 1998; 75: 199-212.
- 352 14. Halliwell B. The antioxidant paradox. *Lancet* 2000; 355: 1179-1180.
- 353 | 15. Branen AL. Toxicology and biochemistry of butylated hydroxyanisole and butylated  
354 hydroxytoluene. *Journal of the American Oil Chemists' Society* 1975; 5: 59-63.
- 355 | 16. Grice HP. Enhanced tumour development by butylated hydroxyanisole (BHA) from the  
356 | prospective of effect on fore-stomach and [oesophageal](#) squamous epithelium.  
357 *Food and Chemical Toxicology* 1988; 26: 717-723.
- 358 | 17. Wichi HC. Safety evaluation of butylated hydroxytoluene (BHT) in the liver, lung and  
359 | gastrointestinal tract. *Food and Chemical Toxicology* 1986; 24: 1127-1130.
- 360 | 18. Persoone G. *Proceeding of the International Symposium on Brine Shrimp, Artemiasalina.*  
361 *Universa Press, Witteren, 1980, 1-3.*
- 362 | 19. Meyer BN, Putnam JE, Jacobsen LB, Nichols DE, and McLaughlin JL. *Planta Medica* 1982;  
363 45: 31-32.
- 364 | 20. Bora P, Kumar Y. Floristic diversity of Assam. Study of pabitora wildlife sanctuary. Daya  
365 Publishing House, Delhi, 2003.
- 366 | 21. Nadkarni AK. *The Indian materia medica*. Vol. 2, Popular Prakashan, Bombay, 1999.
- 367 | 22. Kirtikar KR, Basu BD. *Indian Medicinal Plants*. Vol. 2, International Book Distributors,  
368 Dehra Dun. 1999.
- 369 | 23. Chatterjee A, Pakrashi S. *The treatise on Indian medicinal plants*. Vol. 5, Publication and  
370 Information Directorate, CSIR, Delhi. 1997.
- 371 24. Van Wagenen BC, Larsen R, Cardellina JHIII, Ran dazzo D, Lidert ZC, Swithenbank C.  
372 Ulosantoin a potent insecticide from the sponge *Ulosaruetzleri*. *Journal of Organic*  
373 *Chemistry* 1993; 58: 335-337.
- 374 25. Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: a  
375 | review. *Internationale Pharmaceutica Scientia* 2011; 1: 103-104.
- 376 26. Ahmed ZU, Bithi SS, Khan MM, Hossain MM, Suriya S, Rony SR. Phytochemical  
377 | screening, antioxidant and cytotoxic activity of fruit extracts of *Calamustenuis Roxb.* *Journal*  
378 *of Coastal Life Medicine*. 2014; 2(8):645-50.
- 379 27. Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Dagainawala HF. Development  
380 of an *in vitro* model to study clot lysis activity of thrombolytic drugs. *Thrombosis Journal*  
381 2006; 4: 14.
- 382 28. Shinde UA, Phadke AS, Nair AM, Mungantiwar AA, Dikshit VJ, Saraf MN. Membrane  
383 stabilizing activity - a possible mechanism of action for the anti-inflammatory activity of  
384 | *Cedrus deodara* wood oil. *Fitoterapia* 1999; 70: 251-257.
- 385 29. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standard  
386 single disc method. *American Journal of Clinical Pathology* 1966; 45: 493-96.

- 387 30. William WB, Cuvelier ME, Berset C. Use of Free Radical Method to Evaluate Antioxidant  
388 Activity. LWT-Food Science and Technology 1995; 28(1): 25- 30.
- 389 31. Maclaughlin JL, Anderson JE, Rogers LL. The use of biological assays to evaluate  
390 botanicals. Drug Information Journal 1998; 32: 513-524.
- 391 32. Omale J, Okafor PN. Comparative antioxidant capacity, membrane stabilization, polyphenol  
392 | composition and cytotoxicity of the leaf and stem of *Cissus multistriata*. African Journal of  
393 Biotechnology 2008; 7:3129-3133.
- 394 33. Shahriar M, Khair NZ, Sheikh Z, Chowdhury SF, Kamruzzaman M, Bakhtiar MSI *et al.*  
395 | Characterization of phytoconstituents and potential bioactivity of *Annona reticulata reticulata*  
396 L. leaf extract. Journal of Pharmacognosy and Phytochemistry 2016; 5(1): 42-45.
- 397 34. Sannigrahi S, Mazumder UK, Pal D, Mishra SL, Maity S. Flavonoids of *Enhydra fluctuans*  
398 | *fluctuans* exhibits analgesic and anti-inflammatory activity in different animal models.  
399 Pakistan journal of Pharmaceutical Sciences 2011; 24(3): 369-375.
- 400 35. Bhakta J, Majumdar P, Munekage Y. Antimicrobial efficacies of methanol extract of  
401 | *Asteracantha longifolia*, *Ipomoea aquatica* and *Enhydra fluctuans* against *Escherichia coli*,  
402 *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Micrococcus luteus*. Internet Journal  
403 of Alternative Medicine 2009;7(2).
- 404 36. Sannigrahi S, Mazuder UK, Pal DK, Parida S, Jain S. Antioxidant potential of crude extract  
405 | and different fractions of *Enhydra fluctuans* Lour. Iranian journal of pharmaceutical  
406 research 2010;9(1):75.
- 407 37. Ghosh D, Ray S, Ghosh K, Micard V, Chatterjee UR, Ghosal PK, Ray B. Antioxidative  
408 | carbohydrate polymer from *Enhydra fluctuans* and its interaction with bovine serum albumin.  
409 Biomacromolecules 2013; 14(6):1761-1768.
- 410 38. Krishnaraju AV, Rao TV, Sundararaju D, Vanisree M, Tsay HS, Subbaraju GV. Biological  
411 | screening of medicinal plants collected from Eastern Ghats of India using *Artemia salina*  
412 (brine shrimp test). International Journal of Applied Science and Engineering 2006; 4(2):115-  
413 125.
- 414 | 39. Sannigrahi S, Mazumder UK, Mondal A, Pal D, Mishra SL, Roy S. Flavonoids of *Enhydra*  
415 *fluctuans* exhibit anticancer activity against Ehrlich's ascites carcinoma in mice. Natural  
416 product communications. 2010; 5(8):1239-1242.
- 417 | 40. Patil KS, Majumder P, Wadekar RR. Effect of *Enhydra fluctuans* Lour. leaf extract on  
418 phagocytosis by human neutrophils. Journal of Natural Remedies 2008; 8(1):76-81.

Formatted: Font: Italic